An integrated analysis of nonmenstrual adverse events with Implanon® (Retraction in: Contraception (2004) 70:5 (433))

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

This integrated analysis evaluates nonmenstrual adverse events, blood pressure, and body weight changes during the use of the single-rod etonogestrel-containing contraceptive implant, Implanon®; these aspects are compared for Implanon and Norplant®, the six-capsule implant containing levonorgestrel. Overall, 47% of Implanon users had drug-related adverse events, whereas in the comparative studies the figure for those using Implanon (61%) was slightly lower than that for Norplant users (69%). In all Implanon studies, 12 of 1716 women (0.7%) were affected by serious adverse events that were considered drug related. In comparative studies three of the 689 Implanon users (0.4%) and one of 689 Norplant users (0.1%) had such experiences. The most frequently reported drug-related adverse events were acne, breast pain, headache, and weight gain. The adverse events that most often caused discontinuation of Implanon were weight gain and ache. The development or aggravation of acne was a frequent adverse event (in 18.5% of Implanon and 22.3% of Norplant users in the comparative studies) but individual studies indicated that there were also many subjects whose acne improved during implant use. There were gradual increases in body weight over time but these may be only partly attributable to implant use and partly attributable to normal increases over time.

Original languageEnglish
JournalContraception
Volume58
Issue number6 SUPPL.
DOIs
Publication statusPublished - Dec 1998

Fingerprint

Contraception
Levonorgestrel
Acne Vulgaris
Drug-Related Side Effects and Adverse Reactions
Weight Gain
Mastodynia
etonogestrel
Body Weight Changes
Contraceptive Agents
Capsules
Headache
Body Weight
Blood Pressure
Pain
Pharmaceutical Preparations

Keywords

  • Adverse events
  • Contraceptives
  • Etonogestrel
  • Implanon®
  • Implant
  • Progestin-only
  • Safety

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynaecology

Cite this

@article{eb0ac108158e4b81833bcf453ddd97ad,
title = "An integrated analysis of nonmenstrual adverse events with Implanon{\circledR} (Retraction in: Contraception (2004) 70:5 (433))",
abstract = "This integrated analysis evaluates nonmenstrual adverse events, blood pressure, and body weight changes during the use of the single-rod etonogestrel-containing contraceptive implant, Implanon{\circledR}; these aspects are compared for Implanon and Norplant{\circledR}, the six-capsule implant containing levonorgestrel. Overall, 47{\%} of Implanon users had drug-related adverse events, whereas in the comparative studies the figure for those using Implanon (61{\%}) was slightly lower than that for Norplant users (69{\%}). In all Implanon studies, 12 of 1716 women (0.7{\%}) were affected by serious adverse events that were considered drug related. In comparative studies three of the 689 Implanon users (0.4{\%}) and one of 689 Norplant users (0.1{\%}) had such experiences. The most frequently reported drug-related adverse events were acne, breast pain, headache, and weight gain. The adverse events that most often caused discontinuation of Implanon were weight gain and ache. The development or aggravation of acne was a frequent adverse event (in 18.5{\%} of Implanon and 22.3{\%} of Norplant users in the comparative studies) but individual studies indicated that there were also many subjects whose acne improved during implant use. There were gradual increases in body weight over time but these may be only partly attributable to implant use and partly attributable to normal increases over time.",
keywords = "Adverse events, Contraceptives, Etonogestrel, Implanon{\circledR}, Implant, Progestin-only, Safety",
author = "J. Urbancsek",
year = "1998",
month = "12",
doi = "10.1016/S0010-7824(98)00122-X",
language = "English",
volume = "58",
journal = "Contraception",
issn = "0010-7824",
publisher = "Elsevier USA",
number = "6 SUPPL.",

}

TY - JOUR

T1 - An integrated analysis of nonmenstrual adverse events with Implanon® (Retraction in

T2 - Contraception (2004) 70:5 (433))

AU - Urbancsek, J.

PY - 1998/12

Y1 - 1998/12

N2 - This integrated analysis evaluates nonmenstrual adverse events, blood pressure, and body weight changes during the use of the single-rod etonogestrel-containing contraceptive implant, Implanon®; these aspects are compared for Implanon and Norplant®, the six-capsule implant containing levonorgestrel. Overall, 47% of Implanon users had drug-related adverse events, whereas in the comparative studies the figure for those using Implanon (61%) was slightly lower than that for Norplant users (69%). In all Implanon studies, 12 of 1716 women (0.7%) were affected by serious adverse events that were considered drug related. In comparative studies three of the 689 Implanon users (0.4%) and one of 689 Norplant users (0.1%) had such experiences. The most frequently reported drug-related adverse events were acne, breast pain, headache, and weight gain. The adverse events that most often caused discontinuation of Implanon were weight gain and ache. The development or aggravation of acne was a frequent adverse event (in 18.5% of Implanon and 22.3% of Norplant users in the comparative studies) but individual studies indicated that there were also many subjects whose acne improved during implant use. There were gradual increases in body weight over time but these may be only partly attributable to implant use and partly attributable to normal increases over time.

AB - This integrated analysis evaluates nonmenstrual adverse events, blood pressure, and body weight changes during the use of the single-rod etonogestrel-containing contraceptive implant, Implanon®; these aspects are compared for Implanon and Norplant®, the six-capsule implant containing levonorgestrel. Overall, 47% of Implanon users had drug-related adverse events, whereas in the comparative studies the figure for those using Implanon (61%) was slightly lower than that for Norplant users (69%). In all Implanon studies, 12 of 1716 women (0.7%) were affected by serious adverse events that were considered drug related. In comparative studies three of the 689 Implanon users (0.4%) and one of 689 Norplant users (0.1%) had such experiences. The most frequently reported drug-related adverse events were acne, breast pain, headache, and weight gain. The adverse events that most often caused discontinuation of Implanon were weight gain and ache. The development or aggravation of acne was a frequent adverse event (in 18.5% of Implanon and 22.3% of Norplant users in the comparative studies) but individual studies indicated that there were also many subjects whose acne improved during implant use. There were gradual increases in body weight over time but these may be only partly attributable to implant use and partly attributable to normal increases over time.

KW - Adverse events

KW - Contraceptives

KW - Etonogestrel

KW - Implanon®

KW - Implant

KW - Progestin-only

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=0032459376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032459376&partnerID=8YFLogxK

U2 - 10.1016/S0010-7824(98)00122-X

DO - 10.1016/S0010-7824(98)00122-X

M3 - Article

C2 - 10095981

AN - SCOPUS:0032459376

VL - 58

JO - Contraception

JF - Contraception

SN - 0010-7824

IS - 6 SUPPL.

ER -